BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
58.30
+1.44 (2.53%)
Aug 13, 2025, 4:00 PM - Market closed
BioMarin Pharmaceutical Stock Forecast
Stock Price Forecast
According to 22 professional analysts, the 12-month price target for BioMarin Pharmaceutical stock ranges from a low of $65 to a high of $126. The average analyst price target of $93.14 forecasts a 59.76% increase in the stock price over the next year.
Price Target: $93.14 (+59.76%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for BioMarin Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 6 | 6 | 6 |
| Buy | 11 | 11 | 10 | 10 | 11 | 11 |
| Hold | 6 | 6 | 6 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 22 | 22 | 22 | 22 | 23 | 23 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $101 → $106 | Strong Buy | Maintains | $101 → $106 | +81.82% | Aug 6, 2025 |
| UBS | UBS | Strong Buy Maintains $113 → $114 | Strong Buy | Maintains | $113 → $114 | +95.54% | Aug 5, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $97 → $96 | Buy | Maintains | $97 → $96 | +64.67% | Jul 22, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $108 → $113 | Buy | Maintains | $108 → $113 | +93.83% | Jul 14, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $124 → $104 | Strong Buy | Maintains | $124 → $104 | +78.39% | May 5, 2025 |
Financial Forecast
Revenue This Year
3.21B
from 2.85B
Increased by 12.34%
Revenue Next Year
3.53B
from 3.21B
Increased by 10.01%
EPS This Year
3.52
from 2.21
Increased by 59.49%
EPS Next Year
4.40
from 3.52
Increased by 24.92%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.4B | 3.9B | 4.3B | ||
| Avg | 3.2B | 3.5B | 3.8B | ||
| Low | 3.0B | 3.1B | 3.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 17.7% | 22.1% | 23.1% | ||
| Avg | 12.3% | 10.0% | 8.6% | ||
| Low | 6.1% | -2.3% | -7.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.11 | 5.42 | 6.79 | ||
| Avg | 3.52 | 4.40 | 5.24 | ||
| Low | 2.49 | 2.97 | 3.53 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 86.4% | 53.8% | 54.5% | ||
| Avg | 59.5% | 24.9% | 19.1% | ||
| Low | 12.8% | -15.7% | -19.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.